| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 From the St. Erik’s Eye Hospital, Stockholm, Sweden; the 2 Department of Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden; the 3 Regina Elena Cancer Institute, Rome, Italy; and the 4 Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York.
PURPOSE. Malignant transformation of cells is frequently associated with abnormalities in human leukocyte antigen (HLA) expression. These abnormalities may play a role in the clinical course of the disease, because HLA antigens mediate interactions of tumor cells with T cells and NK cells. Uveal melanoma is a highly malignant tumor of the eye and is characterized by a hematogenic spread to the liver. Little is known about the role of HLA expression in progression of this malignant disease.
METHODS. In the present study HLA class I antigen, ß2-microglobulin (ß2-m), and HLA class II antigen expression was analyzed in primary uveal melanoma lesions by immunoperoxidase staining with monoclonal antibodies of 65 archival clinical samples. The results were correlated with the clinical course of the disease.
RESULTS. HLA class I antigen expression and ß2-m expression were downregulated in 40 and 35 lesions, respectively. HLA class II antigens were expressed in 30 lesions. Patients with high HLA class I, including ß2-m, and HLA class II antigen expression in their primary melanoma lesions had a significantly decreased survival (P = 0.009, P < 0.001, and P = 0.006, respectively).
CONCLUSIONS. The findings argue against a major role of cytotoxic T-lymphocyte (CTL)–mediated control of tumor growth in the clinical course of uveal melanoma and are compatible with a potential role of NK-cell–mediated control of hematogenic metastatic spread.
This article has been cited by other articles:
|
|
 |
|
  K. Hallermalm, K. Seki, A. De Geer, B. Motyka, R. C. Bleackley, M. J. Jager, C. J. Froelich, R. Kiessling, V. Levitsky, and J. Levitskaya Modulation of the Tumor Cell Phenotype by IFN-{gamma} Results in Resistance of Uveal Melanoma Cells to Granule-Mediated Lysis by Cytotoxic Lymphocytes J. Immunol., March 15, 2008; 180(6): 3766 - 3774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Maat, L. V. Ly, E. S. Jordanova, D. de Wolff-Rouendaal, N. E. Schalij-Delfos, and M. J. Jager Monosomy of Chromosome 3 and an Inflammatory Phenotype Occur Together in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 505 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Holling, M. W. T. Bergevoet, L. Wilson, M. C. J. A. Van Eggermond, E. Schooten, R. D. M. Steenbergen, P. J. F. Snijders, M. J. Jager, and P. J. Van den Elsen A Role for EZH2 in Silencing of IFN-{gamma} Inducible MHC2TA Transcription in Uveal Melanoma J. Immunol., October 15, 2007; 179(8): 5317 - 5325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Maat, G. W. Haasnoot, F. H. J. Claas, N. E. Schalij-Delfos, G. M. T. Schreuder, and M. J. Jager HLA Class I and II Genotype in Uveal Melanoma: Relation to Occurrence and Prognosis Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 3 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Albers, K. Abe, J. Hunt, J. Wang, A. Lopez-Albaitero, C. Schaefer, W. Gooding, T. L. Whiteside, S. Ferrone, A. DeLeo, et al. Antitumor Activity of Human Papillomavirus Type 16 E7-Specific T Cells against Virally Infected Squamous Cell Carcinoma of the Head and Neck Cancer Res., December 1, 2005; 65(23): 11146 - 11155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-G. He, E. Mayhew, J. Mellon, and J. Y. Niederkorn Expression and Possible Function of IL-2 and IL-15 Receptors on Human Uveal Melanoma Cells Invest. Ophthalmol. Vis. Sci., December 1, 2004; 45(12): 4240 - 4246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P N Tulley, M Neale, D Jackson, J S Chana, R Grover, I Cree, A O Grobbelaar, and G D Wilson The relation between c-myc expression and interferon sensitivity in uveal melanoma Br. J. Ophthalmol., December 1, 2004; 88(12): 1563 - 1567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hallermalm, A. De Geer, R. Kiessling, V. Levitsky, and J. Levitskaya Autocrine Secretion of Fas Ligand Shields Tumor Cells from Fas-Mediated Killing by Cytotoxic Lymphocytes Cancer Res., September 15, 2004; 64(18): 6775 - 6782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Krishnakumar, S A Lakshmi, D Abhyankar, and J Biswas Transporter associated protein expression in uveal melanoma Br. J. Ophthalmol., July 1, 2004; 88(7): 925 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Krishnakumar, D. Abhyankar, A. L. Sundaram, V. Pushparaj, M. P. Shanmugam, and J. Biswas Major Histocompatibility Antigens and Antigen-processing Molecules in Uveal Melanoma Clin. Cancer Res., September 15, 2003; 9(11): 4159 - 4164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Alizadeh, K. Howard, J. Mellon, E. Mayhew, D. Rusciano, and J. Y. Niederkorn Reduction of Liver Metastasis of Intraocular Melanoma by Interferon-{beta} Gene Transfer Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 3042 - 3051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Anastassiou, V. Rebmann, S. Wagner, N. Bornfeld, and H. Grosse-Wilde Expression of Classic and Nonclassic HLA Class I Antigens in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 2016 - 2019. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
